Business
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes – – Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event – – Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML – – $107.1 Million in Cash and Cash Equivalents as of March 31, 2026;
About this update from Sellas Life Sciences Group, Inc.
[{"type":"image","alt":"SELLAS Life Sciences Group, Inc.","displaySize":"","headline":null,"caption":"SELLAS Life Sciences Group, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/1570633a12e0dc941a3e2343b15473ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GShh9i.pLECdgZkEWUY8Tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1570633a12e0dc941a3e2343b15473ec","width":300,"height":99},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/GShh9i.pLECdgZkEWUY8Tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1570633a12e0dc941a3e2343b15473ec","width":300,"height":99}},"lazy":false},{"type":"text","content":"– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11, 2026; SELLAS Remains Blinded to Trial Outcomes –","length":250,"tagName":"p"},{"type":"text","content":"– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80th Event –","length":88,"tagName":"p"},{"type":"text","content":"– Ongoing Dosing of Patients in Phase 2 Trial of SLS009 in Newly Diagnosed First Line AML –","length":91,"tagName":"p"},{"type":"text","content":"– $107.1 Million in Cash and Cash Equivalents as of March 31, 2026; Additional $7.5 Million in Proceeds Received in Q2 2026 to Date through Warrant Exercises –","length":159,"tagName":"p"},{"type":"text","content":"NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.","length":364,"tagName":"p"},{"type":"text","content":"“The first quarter of 2026 marked an important period for SELLAS as we continued to execute across our clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “We are grateful for the ongoing commitment of the patients, caregiv...